Aeterna Zentaris

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.

CHARLESTON, S.C., July  30, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the abstract on study results of its first pediatric study on macimorelin has been selected for presentation at the 22nd European Congress of Endocrinology (e-ECE 2020) being held September 5-9, 2020.

AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY

CHARLESTON, S.C., July  07, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering of 17,544,516 units at a price to the public of $0.45 per unit and 9,122,150 pre-funded units at a price to the public of $0.4499 per pre-funded unit. Each unit sold in this offering contains one common share and one common warrant to purchase one common share. Each pre-funded unit sold in this offering contains one pre-funded warrant to purchase one common share at an exercise price of $0.0001 per share and one common warrant to purchase one common share. The gross proceeds to the Company from the offering totaled approximately $12 million, before deducting placement agent fees and offering expenses.

AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING

CHARLESTON, S.C., July  01, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a public offering of 26,666,666 units at a price to the public of $0.45 per unit, for gross proceeds of $12 million, before deducting placement agent fees and other offering expenses payable by the Company. Each unit contains one common share (or common share equivalent) and one common warrant to purchase one common share. The common shares (or common share equivalents) and common share warrants included in the units can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about July 7, 2020, subject to satisfaction customary closing conditions.

AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING

CHARLESTON, S.C, June  25, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc.   (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive distribution and related quality agreement (the “Agreement”) with Megapharm Ltd. (“Megapharm”), a leading Israel-based biopharmaceutical company, for the commercialization in Israel and the Palestinian Authority of macimorelin, Aeterna Zentaris’ orally available ghrelin agonist to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and child-onset growth hormone deficiency (“CGHD”). 

AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY

CHARLESTON, S.C., June  04, 2020  (GLOBE NEWSWIRE) --  Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has received a positive decision from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Staff”), granting the Company’s request for an extension through October 5, 2020 to achieve compliance with the minimum $2.5 million stockholders‘ equity requirement for continued listing on The Nasdaq Capital Market. The Staff’s determination followed the Company’s submission of its compliance plan for the Staff’s consideration on May 26, 2020. 

Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements

CHARLESTON, S.C., May  15, 2020  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the results from its Annual General Meeting (“AGM”) held today, May 15, 2020.

Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders

CHARLESTON, S.C., April  15, 2020  (GLOBE NEWSWIRE) --  Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that on April 8, 2020, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum $1.00 per share bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as the bid price for the Company’s common stock had closed below $1.00 per share for the prior 30 consecutive business day period, and that the Company has been provided a grace period of 180 calendar days, through October 5, 2020, to evidence compliance with that requirement. The grace period was granted pursuant to Nasdaq Listing Rule 5810(c)(3)(A). To evidence compliance with the bid price requirement, the Company must report a closing bid price of at least $1.00 per share for a minimum of 10, and generally not more than 20, consecutive business days on or before October 5, 2020.

Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing

– Modifications recommended for some key elements of planned safety and efficacy Study P02 –

AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN

– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN

CHARLESTON, S.C., March  12, 2020  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced  it has settled the previously disclosed class-action lawsuit against it pending in the U.S. District Court for the District of New Jersey.  The settlement payment will be funded entirely by the Company’s insurers. 

AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT

CHARLESTON, S.C., Feb.  21, 2020  (GLOBE NEWSWIRE) --  Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today the closing of its previously announced registered direct offering with several institutional investors in the United States for 3,478,261 common shares, at a purchase price of $1.29375 per share, priced at-the-market under Nasdaq rules. Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 2,608,696 common shares in a concurrent private placement. The warrants have an exercise price of $1.20 per common share, are exercisable immediately and will expire five and one-half years following the date of issuance. The gross proceeds to the Company from the offering totaled approximately $4.5 million, before deducting placement agent fees and offering expenses.

Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market

CHARLESTON, S.C., Feb.  19, 2020  (GLOBE NEWSWIRE) --  Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 3,478,261 common shares at a purchase price of $1.29375 per common share in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million.

Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market

Presentation on Monday, February 17th at 11:30 a.m. ET Presentation on Monday, February 17th at 11:30 a.m. ET

Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

CHARLESTON, S.C., Jan.  27, 2020  (GLOBE NEWSWIRE) --  Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”).

Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

CHARLESTON, S.C., Jan.  08, 2020  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, because the closing bid price of the Company’s common stock for 30 consecutive business days was below $1.00 per share, the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for

Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Aeterna Zentaris (AEZS) a New Buy Stock

CHARLESTON, S.C., Oct.  04, 2019  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective today, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company.

Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

CHARLESTON, S.C., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced the closing of its previously announced offering whereby the Company entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 Million (before placement agent’s fees and expenses) of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement (together, the “Offering”). The combined purchase price for one common share and one warrant was $1.50.

Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering

CHARLESTON, S.C., Sept.  20, 2019  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced today that it has entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 million of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined purchase price for one common share and one warrant will be $1.50.

Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering

Aeterna Zentaris has had a rough go over since April which forced me to jump ship and sell the remaining shares of AEZS. Now, I am looking to return.

Aeterna Zentaris: Considering A Re-Entry After Sell-Off

CHARLESTON, S.C., Aug.  20, 2019  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for personal reasons, effective immediately. The board of directors of the Company has appointed Carolyn Egbert, existing director and Chairperson, to replace Mr. Pollack on the audit committee.

Aeterna Zentaris Announces Director Change

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 107.14% and -3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Aeterna Zentaris Stock (AEZS)